LOGIN  |  REGISTER
Viking Therapeutics
Chimerix

MiMedx Points to The New York Times Article on the Vast Benefits of Placental Tissue

October 08, 2024 | Last Trade: US$9.10 0.02 0.22

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today’s New York Times: “Her Face Was Unrecognizable After an Explosion. A Placenta Restored It.”

The author underscored the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the largely unknown opportunity for a mother to donate her nutrient rich placenta after a healthy C-section delivery. MIMEDX uses this source material to produce the majority of its product offerings today.  

Commenting on the article, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We were delighted to see attention called to this area of patient care and to contribute to this important piece. While MIMEDX is not mentioned by name, two individuals from our “Patient Story” series, Marcella and Phyllis, are prominently featured in the article, showcasing their remarkable recoveries. In both cases our products played a central role.”

Mr. Capper concluded, “We believe this article and the recently-published Nature – Scientific Reports publication will increase awareness about the unique scientific properties and growing clinical use of placental-derived products to treat patients with chronic and other hard-to-heal wounds.”

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB